TABLE 1.
Patients and samples used in this studya
| Variable | Pregnant | First trimester | Second trimester | Third trimester | Not pregnant |
|---|---|---|---|---|---|
| N | 117 | 28 | 36 | 53 | 335 |
| Patient age | |||||
| Mean age | 29.7 | 29.3 | 30.3 | 29.5 | 30.7 |
| 18–24, n (%) | 26 (22.2%) | 8 (28.6%) | 7 (19.4%) | 11 (20.8%) | 72 (21.5%) |
| 25–34, n (%) | 64 (54.7%) | 14 (50.0%) | 18 (50.0%) | 32 (60.4%) | 157 (46.9%) |
| 35–44, n (%) | 27 (23.1%) | 6 (21.4%) | 11 (30.6%) | 10 (18.9%) | 106 (31.6%) |
| Race/ethnicity | |||||
| Black, n (%) | 48 (41.0%) | 14 (50.0%) | 13 (36.1%) | 21 (39.6%) | 138 (41.2%) |
| Hispanic, n (%) | 22 (18.8%) | 2 (7.1%) | 6 (16.7%) | 14 (26.4%) | 53 (15.8%) |
| Other, n (%) | 13 (11.1%) | 4 (14.3%) | 3 (8.3%) | 6 (11.3%) | 30 (9.0%) |
| White, n (%) | 34 (29.1%) | 8 (28.6%) | 14 (38.9%) | 12 (22.6%) | 114 (34.0%) |
| Ninth month, n (%) | 26 (22.2%) | 0 (0.0%) | 0 (0.0%) | 26 (49.1%) | 0 (0.0%) |
| Area deprivation index | 6.3 | 6.6 | 5.9 | 6.4 | 6.4 |
| Charlson score | 0 | 0 | 0 | 0 | 0 |
| Vaccination status | |||||
| Unvaccinated, n (%) | 84 (71.8%) | 20 (71.4%) | 27 (75.0%) | 37 (69.8%) | 244 (72.8%) |
| Vaccinated, n (%) | 33 (28.2%) | 8 (28.6%) | 9 (25.0%) | 16 (30.2%) | 91 (27.2%) |
| Moderna mRNA-1273, n (%) | 12 (10.2%) | 2 (7.2%) | 3 (8.3%) | 7 (13.2%) | 24 (7.2%) |
| Pfizer/BioNtech, n (%) | 21 (18.0%) | 6 (21.4%) | 6 (16.7%) | 9 (17.0%) | 67 (20.0%) |
| Homologous booster, n (%) | 7 (6.0%) | 2 (7.1%) | 2 (5.6%) | 3 (5.7%) | 46 (13.7%) |
| Heterologous booster, n (%) | 1 (0.85%) | 0 (0.0%) | 0 (0.0%) | 1 (1.9%) | 3 (0.90%) |
a
“Vaccinated” includes individuals who received a full two-dose mRNA vaccine regimen and/or received a booster dose prior to infection. “Unvaccinated” includes individuals who had not received any vaccine dose prior to infection. Partially vaccinated individuals were excluded from this study.